CN Mobile Logo

Search form


ASCO 2014 Breast Cancer

ASCO 2014 Breast Cancer

In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.

Dr. Pagani, who presented data on the joint analysis of the IBCSG TEXT and SOFT trials at the 2014 ASCO Annual Meeting, discusses how breast cancer patients in these trials responded to different methods of ovarian suppression.

The breast cancer treatment landscape is changing, and the optimal adjuvant endocrine therapy for premenopausal women with hormone receptor (HR)-positive breast cancer is uncertain.

As part of our coverage of the 2014 ASCO Annual Meeting, we discuss treatment strategies for breast cancer patients who harbor either the BRCA1 or BRCA2 mutation.

Zoledronic acid given every 12 weeks was just as efficacious as the drug administered at the standard dosing schedule of every 4 weeks for breast cancer patients with bone metastases.

After surgery, adjuvant therapy with trastuzumab alone works just as well as trastuzumab combined with lapatinib for women with early-stage HER2-positive breast cancer.

The combined analysis of two phase III clinical trials shows that exemestane, an aromatase inhibitor, may better prevent breast cancer recurrence in women with early-stage hormone receptor–positive breast cancer, as compared with tamoxifen.


Subscribe to ASCO 2014 Breast Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.